How it works
A stabilised GHRH(1-44) analogue that resists enzymatic degradation, producing a sustained, physiological increase in endogenous GH and downstream IGF-1.
Structure: 44 amino acid stabilised GHRH analogue
Reported benefits
- Clinically demonstrated visceral adipose tissue reduction (~15–18%)
- Improved triglycerides in trial populations
- Preliminary evidence for cognitive benefit in older adults
Practical considerations
- Visceral fat returns after discontinuation
- Requires monitoring of fasting glucose and IGF-1
- Expensive relative to other GH secretagogues
Side effects and risks
- Joint pain and swelling
- Injection-site erythema
- Insulin resistance
- Peripheral oedema
Dosing overview
Approved label dose is 2 mg once daily
This describes doses reported in published literature and community protocols. It is not a recommendation, and it is not a substitute for clinical supervision.
Research references
- Falutz et al., 2010 — Tesamorelin in HIV lipodystrophy, phase III